Intellectual Property

Issued and Pending Claims

Our core is IP in-licensed from Harvard for individualized and personalized subtraction, a broadening of the SNEP concept. We have patents issued and pending that:

  • Encompass kits and methods for detecting, diagnosing, and prognosing cancer and other indications by obtaining expression profiles of phagocytes and expression profiles of non-phagocytes and then identifying individualized/personalized differential expression of specific markers for the indication (multi-omic).
  • Encompass methods for detecting, diagnosing, and prognosing disease by obtaining markers from cell-free bodily fluids and markers from non-phagocytic cells and then identifying individualized/personalized differential expression of specific markers for the indication (multi-omic)

There are three patent families for hundreds of specific markers used individually or in combination for detecting, diagnosing and prognosing prostate cancer, and head & neck cancer before and/or after treatment. Our pan-disease test and a plurality of other indication patents are to be filed going forward to include kits, methods, and compositions building further on the above mentioned core patents.